Tramadol Hydrochloride Tablet, Film Coated
Product Images NDC 71610-865

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 71610-865). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0865 15)

Label (71610 0865 15)
Label for Tramadol Hydrochloride USP 50 mg film-coated tablets, package containing 15 tablets. Manufactured by Aphena Pharma Solutions, Cookeville, TN. The label includes storage instructions, dispensing guidance, batch number, expiration date, and a warning that the medication may be habit-forming. NDC number 71610-865-15 is visible.*
FDA Label Image

Aphena (Aphena)

FDA Label Image

Structural Formula (Tramadol HCl Tablets A075977 Scored 1)

Structural Formula (Tramadol HCl Tablets A075977 Scored 1)
Chemical structure of Tramadol Hydrochloride, showing its molecular configuration including a cyclohexane ring, phenol group, and dimethylamine moiety, with the hydrochloride salt component indicated.*
FDA Label Image

Figure 1 (Tramadol HCl Tablets A075977 Scored 2)

Figure 1 (Tramadol HCl Tablets A075977 Scored 2)
A pharmacokinetic graph showing concentration (ng/mL) versus time (hours) for Tramadol and its metabolite M1 after single and multiple oral doses. The plot includes four curves representing Tramadol and M1 concentrations under single and multiple dosing conditions over 48 hours.*
FDA Label Image

Figure 2 (Tramadol HCl Tablets A075977 Scored 3)

Figure 2 (Tramadol HCl Tablets A075977 Scored 3)
A line chart titled 'Protocol CAPSS-047' showing time to discontinuation due to nausea/vomiting over days in a double-blind study. The y-axis represents percent discontinuing, and the x-axis represents days. Two lines compare discontinuation rates for 10 days to 200 mg/day and 16 days to 200 mg/day dosing schedules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.